Quantum BioPharma Reports Successful Clinical Trial Results for Alcohol Detox Drink unbuzzd, QNTM Stock Soars 111% on 600X Volume
The clinical trial confirmed that unbuzzd™ speeds up the reduction of blood alcohol concentration while also alleviating the symptoms of intoxication and hangover.
Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (Upstream: QNTM) announced today the completion of its double-blind, randomized, placebo-controlled crossover design clinical trial (NCT06505239) of its alcohol detox beverage unbuzzd™. The purpose of the clinical trial was to investigate the effects of unbuzzd™ on alcohol metabolism and intoxication.
The clinical trial included male and female participants between the ages of 21 and 43, with weights ranging from 119 lbs to 232 lbs. Compared to the placebo group, the study’s results were statistically significant.
Quantum BioPharma reported that the results of the trial clearly showed that unbuzzd™ accelerated the reduction of blood alcohol concentration (BAC) in the study subjects while simultaneously alleviating the symptoms of intoxication and hangover.
The positive effects of unbuzzd™ were quickly evident within 30 minutes of consuming the dissolved powder. In addition, unbuzzd™ was reportedly well-tolerated and safe, with no adverse effects reported.
Commenting on the study’s results, Dr. Andrzej Chruscinski, Vice President of Clinical and Scientific Affairs at Quantum BioPharma, stated:
“We are thrilled to see such significant and meaningful outcomes in this clinical study. This study confirms the exceptional overall performance of unbuzzd™ to help reduce the acute effects of alcohol intoxication. We are also pleased to see that there were no product-related side effects or safety concerns in this clinical study.”
Unbuzzd™ Clinical Trial Key Findings
- Accelerated Alcohol Metabolism: unbuzzd™ dramatically and rapidly reduced blood alcohol concentration (BAC) in study participants. On average, most participants lowered their BAC more than 40 percent faster within 30 minutes of consuming unbuzzd™ than control subjects. This faster reduction of BAC after consuming unbuzzd™ was statistically significant compared to placebo and was observed at each subsequent measurement of BAC over a four-hour period.
- Rapid Improvements in Alertness: Study participants reported statistically significant improvement in alertness as soon as 30 minutes after consuming unbuzzd™. Participants felt more alert and made fewer cognitive errors within 30 minutes of consuming unbuzzd™, significantly outperforming placebo results.
- Rapid Improvements in Physiologic Changes due to Intoxication: unbuzzd™ lessened the elevation in heart rate and the drop in blood pressure that often accompanies alcohol intoxication, stabilizing both. This result was statistically significant.
- Reduced Perceived Impairment and Mental Fatigue: unbuzzd™ helped alleviate perceived impairment and mental fatigue caused by alcohol intoxication.
- Hangover Relief: Participants in this study noted a statistically significant reduction in hangover symptoms. This included reduced cognitive and physical impairment and reduced headache compared to placebo results at both four hours (67 percent reduction in headache severity) and eight hours after consuming unbuzzd™.
- No Side Effects: unbuzzd™ was well-tolerated by all study participants, with no reported adverse side effects.
Zeeshan Saeed, CEO of Quantum BioPharma added:
“This clinical trial shows that unbuzzd™ is an important addition to the safe and responsible consumption of alcohol. Consumers now have the benefit of knowing that unbuzzd™ can reduce alcohol intoxication, speed the reduction of blood alcohol concentration, restore mental alertness and well-being, and help them avoid the worst symptoms of a hangover.”
About unbuzzd™
unbuzzd™ is a proprietary blend of vitamins and supplements developed by Quantum BioPharma’s world-class team of scientists. The company’s double-blind, placebo-controlled crossover study demonstrated, with statistical significance, that unbuzzd™ accelerates alcohol metabolism and speeds the lowering of blood alcohol concentration. In addition, study participants also rapidly restored their mental alertness, reduced their perceived impairment and fatigue, and avoided the worst effects of a hangover.
The unbuzzd™ formula is licensed to and a registered trademark of Celly Nutrition Corp. unbuzzd™ is available for purchase at unbuzzd.com and Amazon.com.
Quantum BioPharma concluded today’s announcement with the following important reminder:
“Individual results may vary. unbuzzd™ is a dietary supplement. Consuming unbuzzd™ after alcohol ingestion does not permit you to operate a vehicle. Drink responsibly. DO NOT DRINK AND DRIVE.”
QNTM Stock Doubles on 600X Volume
In response to the successful unbuzzd™ clinical trial results, shares of Quantum BioPharma (NASDAQ: QNTM) stock skyrocketed 111.01% to close Tuesday at $6.71.
QNTM traded an astounding 78,510,602 shares, an increase of 62,559% compared to its average daily volume of 125,299. With 1.93 million shares outstanding and a tiny public float of approximately 1 million shares, today’s action saw QNTM’s float turn over 78 times.
As we’ve seen over the past few years, low-float NASDAQ stocks that possess the right ingredients, such as GameStop (NYSE: GME), have experienced huge multi-day and even multi-week runs.
With that considered, today’s massive 111% surge in QNTM stock, which has a tiny float and was backed by insane volume, could very well be the start of an ever-bigger move.
View Quantum BioPharma Interactive Stock Chart on Barchart
Read Next: Why This Small Biotech Stock Could Be Primed for a Breakout
Join the Discussion in the WVC Facebook Investor Group
Do you have a stock tip or news story suggestion? Please email us at Invest@WealthyVC.com.
This report/release/profile is a commercial advertisement and is for general information purposes only. We are engaged in the business of marketing and advertising companies for monetary compensation unless otherwise stated below.
Wealthy VC and its employees are not Registered Investment Advisors, Broker-Dealers or a member of any association for other research providers in any jurisdiction whatsoever and we are not qualified to give financial advice. The information contained herein is based on sources which we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. Wealthy VC encourages readers and investors to supplement the information in these reports with independent research and other professional advice. All information on featured companies is provided by the companies profiled through their website, news releases, and corporate filings, or is available from public sources and Wealthy VC makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure by the profiled companies. Our website and newsletter are for entertainment purposes only. This website is NOT a source of unbiased information. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment.
Release of Liability: Through the use of this email and/or website advertisement, by viewing or using it, you agree to hold Wealthy VC, its operators, owners and employees harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damage (monetary or otherwise), or injury (monetary or otherwise) that you may incur. Wealthy VC-sponsored advertisements do not purport to provide an analysis of any company’s financial position, operations or prospects and this is not to be construed as a recommendation by Wealthy VC or an offer or solicitation to buy or sell any security. WealthyVC and our controlling entity 1000724287 Ontario Ltd have been compensated USD $20,000 for social media marketing and USD $7,500 per month for 3 months for investor relations by Quantum BioPharma Ltd.
None of the materials or advertisements herein constitute offers or solicitations to purchase or sell securities of the companies profiled herein and any decision to invest in any such company or other financial decisions should not be made based upon the information provided herein. Instead, Wealthy VC strongly urges you to conduct a complete and independent investigation of the respective companies and consideration of all pertinent risks. Readers are advised to review SEC periodic reports: Forms 10-Q, 10K, Form 8-K, insider reports, Forms 3, 4, 5 Schedule 13D and all reports published on SEDAR if the company featured is Canadian. Wealthy VC further urges you to consult your own independent tax, business, financial and investment advisors. Investing in micro-cap and growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investor’s investment may be lost or impaired due to the speculative nature of the companies profiled.
The Private Securities Litigation Reform Act of 1995 provides investors with a ‘safe harbor’ in regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical fact and may be “forward-looking statements”. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward-looking statements in this action may be identified through the use of words such as “projects”, “foresee”, “expects”, “will”, “anticipates”, “estimates”, “believes”, “understands”, or that by statements indicating certain actions “may”, “could”, or “might” occur. Understand there is no guarantee past performance will be indicative of future results. Past Performance is based on the security’s previous day’s closing price and the high of-day price during our promotional coverage.
In preparing this publication, Wealthy VC has relied upon information supplied by various public sources and press releases which it believes to be reliable; however, such reliability cannot be guaranteed. Investors should not rely on the information contained in this email and website. Rather, investors should use the information contained in this website as a starting point for doing additional independent research on the featured companies. The advertisements in this email and website are believed to be reliable, however, Wealthy VC and its owners, affiliates, subsidiaries, officers, directors, representatives and agents disclaim any liability as to the completeness or accuracy of the information contained in any advertisement and for any omissions of material facts from such advertisement. Wealthy VC is not responsible for any claims made by the companies advertised herein, nor is Wealthy VC responsible for any other promotional firm, its program or its structure.
